Second myeloablative allogeneic stem cell transplantation (SCT) using cord blood for leukemia relapsed after initial allogeneic SCT

Leuk Res. 2009 Jun;33(6):840-2. doi: 10.1016/j.leukres.2008.10.003. Epub 2008 Nov 7.

Abstract

There are many reports of second allogeneic stem cell transplantation (allo-SCT) using cord blood (CB) for graft failure after initial allo-SCT. However, the efficacy of second allo-SCT using CB for patients with leukemia relapsed after initial allo-SCT is unknown. We report the results of second allo-SCT using CB in seven adult patients with leukemia relapsed after initial allo-SCT. All patients received a myeloablative conditioning regimen including oral busulfan 16 mg/kg, intravenously fludarabine 100mg/m(2) and cyclophosphamide 120 mg/kg. All but one patient had myeloid reconstitution and four patients remain alive at between 4 and 40 months after second SCT. We conclude that second myeloablative allo-SCT using CB may be feasible in selected patients with the relatively younger age, less organ damage and longer time interval between first and second allo-SCT.

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Agents / administration & dosage*
  • Busulfan / administration & dosage
  • Cyclophosphamide / administration & dosage
  • Female
  • Fetal Blood*
  • Humans
  • Male
  • Recurrence
  • Stem Cell Transplantation*
  • Transplantation Conditioning*
  • Transplantation, Homologous
  • Treatment Outcome
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives

Substances

  • Antineoplastic Agents
  • Cyclophosphamide
  • Vidarabine
  • Busulfan
  • fludarabine